| 2026-07-31 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Press release | Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-23 | Press release | Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 |
| 2026-06-23 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Press release | Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-28 | Press release | Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 |
| 2026-04-16 | Press release | Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 Read more |
| 2026-04-14 | Proxy | Definitive proxy statement |
| 2026-02-24 | Press release | Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk test |
| 2026-02-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Press release | Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution |
| 2026-02-23 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-27 | Press release | Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 8-K | Form 8-K/A, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-03 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-07 | 8-K | Form 8-K, Item 5.02 |
| 2025-10-03 | 8-K | Form 8-K, Item 5.02 |
| 2025-08-18 | 8-K | Form 8-K, Item 5.02 |
| 2025-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-07-31 | 8-K | Form 8-K, Item 1.01 |
| 2025-06-05 | 8-K | Form 8-K, Item 5.02 |
| 2025-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2025-04-09 | Proxy | Definitive proxy statement |
| 2025-02-28 | 10-K | Annual report on Form 10-K, FY24 |
| 2025-02-24 | 8-K | Form 8-K, Item 2.02 results |
| 2025-01-15 | 8-K | Form 8-K, Item 2.02 results |
| 2024-12-10 | 8-K | Form 8-K, Item 5.02 |
| 2024-11-26 | 8-K | Form 8-K, Item 7.01 |
| 2024-11-13 | Press release | Third Quarter 2024 GAAP to Non-GAAP Reconciliation |
| 2024-11-08 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2024-11-07 | 8-K | Form 8-K, Item 2.02 results |
| 2024-10-09 | Deck | Investor Day 2024 Download Presentation |